Our experienced team of researchers, physicians, and coordinators are dedicated to excellence in every phase of the trial process, from recruitment, assessments of patients to data management. With a main focus in dermatology, we understand the importance of advancing treatments for skin conditions
and improving the lives of patients.

With a proven track record of successful clinical trials and a reputation for adhering to the highest ethical and safety standards, Zepeda Research is a trusted partner. We have collaborated with multiple pharmaceutical companies, Clinical Research Organizations, and Site Management Organizations, bringing innovative treatments to market and contributing to the advancement of medical science. Our Site is committed to excellence and innovation in clinical research, continuously seeking opportunities for professional development and contributing to the advancement of medical knowledge.

Results with integrity

Zepeda Research delivers results with integrity in all our work, and we always strive to uphold the highest standards of ethical product honesty and transparency following the ICH GPC in everything we do.

Patient-Centered Approach

Zepeda Research adopts a patient-centered approach to everything we do. By placing human needs, values, and behaviors at the forefront of our deign and decision-making processes, we ensure that our solutions are not only effective but also empathetic, intuitive, and impactful for all involved.

Innovation in Action

Zepeda Research is where innovation meets action. We're constantly pushing boundaries, exploring new frontiers to drive meaningful changes in clinical research and patient care.

With more than 15 years of performing clinical trials Phases II, III and IV in diverse medical areas these are some of the clinical trials we have worked in our site in the last years:

Imagen de la Universidad Francisco Marroquín

A randomized, observer-blinded, placebo-controlled study on the safety and efficacy of twice-daily application of SM-030 Gel 0.64% vs. Gel SM-030 0.08% vs. Placebo Gel in adults with melasma. Dermbiont Inc. Phase III. 2024-present.

Safety and efficacy of Fusidic acid in patients with secondary skin infections. Taro Pharm, Phase IV. 2023.

Adaptive open-label design study to explore the Safety and Efficacy of multiple treatment regimens with Akt Inhibitor SM-020 Gel in 1.0% and 0.1% formulations in subjects with seborrheic keratosis. Dermbiont Inc. Phase III. 2021-present.

Safety and Efficacy of twice-daily application o Ruboxistaurin Gel vs. Vehicle Gel vs. Hydroquinone Cream in sun-exposed and sun-protected skin of adults. DermBiont, Inc. Phase IIA. 2022-2023.

Safety and Efficacy of SCD-044 in the treatment of moderate to severe atopic dermatitis. Taro Pharm, Phase IIB. 2022-present.

Safety and Efficacy of SCD-044 in the treatment of moderate to severe psoriasis. Taro Pharm, Phase IIB. 2022-present.

Safety and Efficacy of Mupirocin in secondary infections by Taro Pharm Phase III 2018-2019. (FDA Audit on 4th November to 9th November, 2019, Satisfactory result, no finding 483).

Safety and Efficacy of Fusidic acid in patients with Impetigo. Novum Pharm. Phase III. 2018-2019.

Safety and Efficacy of Ivermectin in patients with Pediculosis. Novum Pharm. Phase III. 2018 Safety and Efficacy of Desoximetasone in Atopic Dermatitis. Novum Pharm. PK Study. 2017-2019.

Safety and Efficacy of Desoximetasone in Pediatric Psoriasis. Novum Pharm. PK Study. 2017-2019.

Safety and Efficacy of permethrin in patients with scabies. Novum Pharm. Phase III 2015-2016.

Safety and Efficacy of Favipiravir in patients with Influenza. PPD. Phase III 2013-2015.

Safety and Efficacy of Mupirocin in secondary infections. Novum Pharma. Phase III 2011.

Safety and Efficacy of Isotretinoin in acne (Isoface) phase IV Procaps. 2006.

David E. Zepeda Reyes MD

Committed to excellence and innovation in clinical research, continuously seeking opportunities for professional development and contributing to the advancement of medical knowledge.

Principal Investigator